Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
about
New targets for therapy in breast cancer: farnesyltransferase inhibitors.Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemiaFarnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.Signal transduction inhibitors in treatment of myelodysplastic syndromesCurrent and future trials of targeted therapies in cutaneous melanomaCrystal structures of the fungal pathogenAspergillus fumigatusprotein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug designTargeting the RAS oncogene.From bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentPhase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumoursExposure-toxicity relationships for tipifarnib in cancer patientsMolecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitorsTargeting protein prenylation for cancer therapyA phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromeA triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumorsTargeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.Targeted therapies for pancreatic cancer.Angiogenesis inhibitors: current strategies and future prospects.Ras farnesylation inhibitor FTI-277 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis.Ras in cancer and developmental diseasesPresent and future evolution of advanced breast cancer therapy.Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient micePromotion of tumor development in prostate cancer by progerinA phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemiasSmall molecule inhibitors in acute myeloid leukemia: from the bench to the clinicEffect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaMulti-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaThe emerging role of the RAB25 small GTPase in cancerRas/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Farnesyltransferase inhibitors reverse taxane resistanceThe synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patientsFarnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.
P2860
Q24796277-E090E745-D677-403E-B2F8-AE9AF338E18FQ24805262-C82951E0-01F6-42A0-B2C3-7CEC708E7996Q25257588-142E4A83-AD54-41F7-BDCA-BC9753CC4A74Q26829903-58B95D86-1C7A-43F9-8D1F-5172463D9D6DQ27022355-A5C312A4-301E-4C1B-A69F-E37C6091D0E6Q27680918-2C75DC57-EF52-4223-81BB-B0306A5D1518Q27687198-F385EE80-208D-4AA4-B789-D5AC0FA498C3Q28533949-4B5B0EB3-6290-4E9D-AC26-460F37B30167Q33201555-6A476B6E-F361-4CD3-A95E-CAF03B80C5F4Q33361738-F3922F2C-62ED-4EAB-A580-BD47BE3C0A66Q33369069-6AF49CD4-0E1D-48C3-A2C1-350483520D77Q33374647-37E097DA-8AC6-4AD0-BB6A-02A15732057CQ33644407-38A25491-9C66-4E7E-B8B8-32D5C6F3B8C1Q33669995-F2A59E90-E8E9-455F-9801-D8D6650FCA5DQ33679239-85F241E3-B707-4571-A3FE-6DCE7AED0710Q33769335-2D6B77E4-96B5-4A56-956F-9AE50CF511CEQ33778138-559AD705-646E-46AE-8DBF-F7FA5F61272BQ33779007-8563381B-4A1C-4FD5-9EAA-395E4905C6FFQ33899923-13E13CAC-8516-48CB-BE77-C67ADB06C180Q34056376-3DCAA872-436F-44C7-985C-2FA059E42DDDQ34152634-D3F1AF20-D89D-4847-B862-87F227E2EBC9Q34202697-62187427-C5F0-4925-BEB7-48291BFB3939Q34274925-6C132F50-326C-4781-9736-04585D2D30B8Q34372342-33309B91-47C1-485E-A0A3-56CB0FCAC3FBQ34413791-38C68FA9-A722-44A1-A021-292DA40132C9Q34486598-C8D5AC5B-6ED9-445C-B338-962757943110Q34629803-5EE28A07-D5F8-4C39-A7D7-AB6C473E6FDEQ34817365-61D9FE9D-E9A1-4B46-B044-51B0290F79C8Q35012724-C297D815-9925-453B-B1FE-5E58D9EE8DB6Q35091519-CFDDBA34-5708-4899-B241-3676FF01DF14Q35117092-C9D9C27B-6427-4731-B582-76A3EBB3D723Q35525569-832D0459-3DC3-4829-A020-708CEEF0246AQ35628954-81AA0A06-25AC-46B9-A744-7D612D3224C7Q35651754-4276D653-97B3-45E3-8236-2EDB3281945FQ35673314-A1582529-CE0D-4941-B983-AC7A1F167594Q35679353-949A64C8-1B84-4FE5-99AB-CE2A76257F3EQ35774556-0AC347F5-2F3B-4E36-84F1-B770A32AB685Q35774565-DA514817-0231-41F4-B68A-1F90A8D56EE9Q35827635-E842113B-FA8F-43AA-9935-0E57DB04B673Q35990656-E9BCC7A6-790B-441F-974B-34BC5F6DB56F
P2860
Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Characterization of the antitu ...... R115777 in vivo and in vitro.
@ast
Characterization of the antitu ...... R115777 in vivo and in vitro.
@en
type
label
Characterization of the antitu ...... R115777 in vivo and in vitro.
@ast
Characterization of the antitu ...... R115777 in vivo and in vitro.
@en
prefLabel
Characterization of the antitu ...... R115777 in vivo and in vitro.
@ast
Characterization of the antitu ...... R115777 in vivo and in vitro.
@en
P2093
P1433
P1476
Characterization of the antitu ...... r R115777 in vivo and in vitro
@en
P2093
P Angibaud
P304
P407
P577
2001-01-01T00:00:00Z